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CHAPTER I 
 
THE ALPHA-2,3_SIALYL T ANTIGEN 
 
Infection and Pathogenesis 
Infective endocarditis is a condition characterized by vegetative growths on the 
heart valves and surrounding tissues.  The illness is associated with symptoms including 
fever, fatigue, and weight loss.
1,2
  Ultimately the damage done by the vegetation can lead 
to abscess and heart failure in the infected individual.  The cause of the condition can be 
traced to cellular adhesion of Streptococcus gordonii to blood platelets and subsequent 
colonization of vascular tissue.  While rarely affecting healthy hearts, those suffering 
from damage are at a higher risk as platelets deposited on the affected tissue offer the 
bacteria an environment in which to proliferate. 
Streptococcus gordonii is a Gram positive bacteria typically associated with the 
oral cavity and the buildup of plaque.
2
 However, should a patient undergo oral surgery or 
should they have a wound exposed by some other means to S. gordonii , the bacteria can 
enter the blood system and cause infection.  Typically this would not present an issue as 
the bacteria would swiftly be carried out naturally by the body’s immune system, but in 
the case of patients who may be suffering from heart damage the bacteria becomes more 
virulent.  Deposits of platelets left behind provide a surface for bacterial adhesion and 
once the cells adhere, a biofilm is excreted which prevents the colony from being washed 
 2 
away into the bloodstream.  With this protective barrier, the bacteria can grow more 
freely and becomes more invasive causing inflammation and damage to the tissue in and 
around the heart.    
The typical course of treatment for the disease is a schedule of antibiotics, but 
other interests lay in the prevention of adherence.  In this sense, a small molecule could 
potentially be developed that would block binding of the bacteria to blood cells.   Little is 
known of the actual mode of binding of S. gordonii to platelets, but many groups have 
begun to study these events and some light has been shed on the subject in recent years. 
In their studies, Bensing and Sullam discovered a mutant strain of S. gordonii 
which had its binding activity reduced to 50% of the wild type strain.
2,3
  While 
phenotypically the same, genetic sequencing showed the deletion of a 8kb region of DNA 
from the genome.   Encoded in this region were two secretory proteins  secY and secA.  
Typically, such proteins are necessary for the translocation of vital proteins across cell 
membranes, but in the case of S. gordonii they were not necessary for cell growth and 
survival.  Further examination of the surrounding genes lead to the discovery of an 
upfield, cell surface protein that the researchers dubbed GspB.  It was assumed that this 
protein must be related to the ability of the bacteria to colonize heart tissue and adhere to 
cellular tissue. 
In further publications, Bensing and Sullam have confirmed the dependence of S. 
gordonii on the protein GspB for platelet binding in addition to the fact that nine other 
species of Gram positive bacteria are known to contain homologues of this highly 
conserved protein.  A key difference in the structure of GspB and its homologues resides 
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in BR (basic region) of the enzyme.  It is believed that these differences are what impart 
the selectivity associated with the members of the family for binding to cellular surfaces.  
In particular, GspB has been shown to selectively bind the alpha linked 2,3-ST antigen 
over related carbohydrates.  In the attempt to identify the target receptor protein for cell 
surface binding, Western Blot analysis showed the predominant candidate was the known 
cell surface protein GPIba, in which the sialic acid moiety is bound in the requisite 
configuration.  It was also determined through use of fusion proteins that GspB did not 
bind any other associated cell surface proteins.
3
  This information gives us some insight 
into how and where these proteins interact. 
The mucin family of sialic acid associated glycopeptides was first discovered in 
the 1930’s by two separate researchers.4  Blix isolated sialic acid from the submaxillary 
mucin and Klenk found a neuraminic acid derivative in the brain glycolipids.  Since that 
time, much research has been done on the synthesis of glycoproteins and investigation 
into their importance.   Sialic acid itself is associated with cell surface recognition, cell 
communication, and immune system response.  It is of little surprise that it should play a 
role in the mediation of cell surface interaction between S. gordonii and blood platelets. 
Epithelial cancer cells are known to be rich in aberrantly expressed alpha-O-
linked gylcosides and related studies have shown that introducing a synthetic 
carbohydrate can induce an immune-response in both mouse and human studies.  This 
sparked the interest of using and developing these types of carbohydrates as synthetic 
vaccines against various forms of epithelial cancers.  In one study by Danishefsky and 
co-workers, it was shown that by using a T-antigen disaccharide coupled to a carrier 
 4 
protein, mice could be immunized against MCF-7 cancer cells leading to cell specific 
lysis.
5
 
Fukuda has done significant work in the structural determination of the tumor 
associated oligosaccharides, many of which differ simply in the saccharide units or the 
linkages.
6
  This work was published in two subsequent papers, of which one elucidates 
the structure of the trisaccharide associated with the 2,3-ST antigen. One of the 
predominant researchers in the field, Samuel Danishefsky, has published numerous 
syntheses of various blood associated antigens, including the 2,3-ST antigen which is of 
interest in the case of GspB and binding of S. gordonii to platelets.   It is this work that 
we follow in order to synthesize our glycopeptides.
7,8,9
 
 
 
Figure 1.  Structure of the 2,3-ST Antigen (R = Me or R =H). 
 
Given that the selectivity for GspB and its homologues is imparted by the BR, it is 
assumed that this region contains the active site responsible for mediating binding to 
GPIba.  The short section of amino acids has been cloned, purified, and crystallized in an 
attempt to determine the structure of the active site by the lab of Dr. Tina Iverson 
(Vanderbilt University).  Unfortunately, there has not been much luck in elucidating 
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where the protein would actually bind the respective carbohydrate.  Our work revolves 
around the synthesis of the known 2,3-ST antigen in the hopes that co-crystallization 
would divulge definitively where and how the protein binds its associated carbohydrate 
ligand (i.e. 2,3-ST antigen).  We hope to successfully visualize the native protein and 
carbohydrate without modification, however, given the serine rich nature of the protein 
we may require attachment of a tag to the carbohydrate ligand in order to aid in locating 
the binding site. 
 
GspB Probe Synthesis 
Starting from commercially available D-galactal, we were able to protect the C6 
alcohol as a silyl ether.  From here, initially we had tried to protect the 3,4-diol as an 
acetonide but unfortunately found that during the process, we added methanol to the 
glycal double bond to form the corresponding methyl acetal.  In a subsequent attempt, we 
were able to successfully protect the diol as the carbonate, but attempts to oxidize the 
compound to the azido nitrate proved unfruitful.  Consulting the literature, it was 
discovered that under the neutral conditions of DDQ and 2,2 dimethoxypropane we could 
successfully protect the 3,4-diol of 1.3.
10
  Using CAN and NaN3, we were then able to 
form the azido-nitrate as described in Danishefsky’s earlier work.  Hydrolysis of the 
nitrate using thiophenol gave the free hydroxyl at the anomeric position, which was 
converted to the trichloroacetimidate to provide the glycosyl donor. 
The serine donor  required for the coupling to glycosyl donor 1.6 was prepared 
starting from commercially available O-t-butyl-N-Fmoc-serine via benzylation of the 
 6 
carboxylic acid followed by acid promoted hydrolysis of the t-butyl ether to give 1.7a.
11
  
The donor and acceptor were subsequently coupled using TMSOTf as the promoter to 
afford the alpha-linked product.  Using iodine and methanol, both the silyl group and 
acetonide were cleaved to afford an intermediate triol which was in turn protected as the 
C6 TBS silyl ether (1.8??) according to literature precedence.
12
 
 
 
Figure 2. Synthesis of serine appended D-galactal moiety  
 
To form the requisite disaccharide for the final coupling, commercially available 
tetra-O-acetyl, N-acetyl neuraminic acid was condensed with chloro pinacolphosphite to 
give 1.10 as a white solid.  This glycosyl donor was subjected to TMSOTf promoted 
coupling with previously prepared 6-O-TIPS-D-galactal (1.3) to form disaccharide 1.11.  
Epoxidation of glycal 1.10 with dimethyldioxirane followed by immediate oxirane 
opening with ethane thiol under acidic conditions gave thioglycoside 1.11.  The C2 
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hydroxyl group was protected as a benzoate and the silyl group was exchanged for an 
acetate to furnish our required glyclosyl donor. 
 
 
Figure 3.  Synthesis of the sialic acid disaccharide donor 1.13 
 
For the key coupling of 1.8 and 1.13 we planned to employ the Fraiser-Reid 
protocol (NIS/TFA in dichloromethane).  From that point, the silyl group will be 
removed using HCl in THF followed by acetylation of the primary alcohol.  The azide 
will be reduced/coupled using thioacetic acid to furnish the corresponding acetamide.  
Morpholine will remove the Fmoc protecting group and the free amine will be acetylated.  
All of these protocols are based on Danishefsky’s earlier synthesis of the 2,3-ST antigen.  
It is at this point that we could exchange the acetyl group for a linked fluorescent tag.  
This could aid in the visualization of our compound bound to the protein structure.  
 8 
Hydrogenation removes the benzyl group and saponification opens up the lactone and the 
benzoate is removed to yield the desired compound. 
 
 
 Figure 4.  Completion of the 2,3-ST Antigen 
Conclusions 
The basic region is responsible for determining the selectivity of GspB and related 
proteins.  Using the 2,3-ST antigen, we hope to probe the small basic region of the 
protein.  After completion of the synthetic route, future work will entail the co-
crystallization of our synthetic trisachharide with the BR of GspB followed by 
crystallographic experiments to visualize the protein-carbohydrate complex.  We hope 
that this would help to determine the size, shape, and environment of the active site.  
Furthermore, once the active site has been identified it is foreseeable that a library of 
small molecule inhibitors could be developed to screen against GspB for activity.  Using 
this information, one could envision developing a treatment for the disease which would 
not rely on the efficacy of antibiotics on killing the infection, but would rather prevent the 
infection from spreading. 
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CHAPTER II 
 
BAUMYCIN 
 
History in Brief 
Anthracyclines are an interesting class of natural products of which the first 
reported isolation of rhodomycin dates back to 1950 by Brockman and Bauer.
13
  This 
class of natural products has shown high efficacy as antitumor agents in various lines of 
cancer cells as well as antibiotic activity.  Doxorubicin (adriamycin) isolated from S. 
peucettius was the first of the class to be approved for clinical usage in 1974.
13
 
The mechanism of action of the anthracycline class is in part what makes them 
interesting to researchers.  Anthracyclines are known to intercalate DNA and cause an 
unwinding of the helical structure.  Additionally certain members such as doxorubicin 
and daunorubicin can covalently crosslink segments of DNA. The amine moiety of the 
daunosamine sugar can act as a crosslinking agent in combination  with formaldehyde 
and irreversibly link with DNA through a guanine amine.  Furthermore, it has been 
shown that such drugs can stabilize a transient form of the topoisomerase II enzyme in its 
cleavable state.  This inhibits DNA and RNA synthesis halting the process of cellular 
division.
13
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Figure 5. Some common anthracyclines. 
 
Baumycins were first described by Umezawa et al in 1977 as 3 epimeric pairs of 
anthracycline compounds (A1/A2, B1/B2, C1/C2), isolated from S. coeruleorubidus 
ME130-A4.
14
  It has been shown that baumycins A1/A2 are the major product of 
fermentations for several species of Streptomyces, leading to the assumption they are the 
final biosynthetic product rather than daunomycin and that the hydrolysis of the acetal is 
an artifact of isolation.
13
 
Baumycin A1 exhibited high efficacy against leukemia cells (L1210) but the 
members of the baumycin family were not pursued as clinical candidates because of their 
instability and difficulty in recovering them from fermentation broths.
13
  The acetal 
moiety of baumycin is conjectured to derive from the condensation of the 4’-hydroxyl of 
daunosamine with a carbohydrate via a glycosyltransferase, however, conversion to the 
acetal is not fully understood and is under investigation.  Of particular note as well is that 
the stereochemistry of the acetal has never been elucidated. 
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Baumycin has been isolated from a cave dwelling actinomycete bacteria by Dr. 
Brian Bachmann’s group (Vanderbilt University).  This suggests that the secluded 
ecosystems found in subterranean environments may yield species which produce 
interesting, active secondary metabolites.  Starting from the advanced intermediate 
daunomycin, a semisynthetic route to baumycin has been proposed.  Through synthetic 
methods, the different stereoisomers can be generated in order to assign the relative 
configuration of the acetal substituent of the natural product.   
Three stereocenters are unassigned for the dissacharide, namely the configuration 
of the anomeric center, the relative stereochemistry of the secondary alcohol at C3 as 
well as the stereochemistry at C5.  It is hypothesized that the diastereomers could arise 
from a mixed reduction product at the C3 center, but we cannot rule out the possibility of 
a mixture of D and L sugars as evidenced by work done on rubeomycin or potentially an 
anomeric mixture
15
.  One stereocenter is set using L-rhamnose in our synthesis while the 
anomeric position and the geometry about the secondary alcohol are to be determined via 
experiment.  However, as nature tends to favor the alpha-anomer, this will be our main 
consideration for the stereochemistry at C1. 
Synthetic Strategy 
It has been hypothesized that baumycin could come from the oxidative cleavage 
of a 3,4 hydroxy sugar followed by reduction of the corresponding keto-aldehyde
13
.  This 
2-deoxy-glycoside could arise from the oxidative coupling of daunomycin with an 
appropriately protected glycal followed by reduction and deprotection.  The 2-deoxy 
glycal can be obtained from the sugar rhamnose (Figure 6). 
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Figure 6. Baumycin retrosynthesis 
Conversion of L-rhamnose to L-rhamnal serves as a starting point for the 
synthesis and defines the C5’ stereocenter.  Following a modified Fischer-Zach protocol, 
L-rhamose is peracetylated followed by conversion to the crude bromide (Scheme 2).  
Using a buffered solution of zinc and copper sulfate, the bromide is converted to the 3,4-
di-O-acetyl rhamnal.
16
  Deprotection of the alcohols allows the selective oxidation of the 
allylic alcohol by PDC and treatment with methyllithium yields the known C3 branched 
glycals in a 4:1 ratio.
17
 Protection of the secondary alcohol as the acetate provides the 
necessary substrate for the key oxidative coupling of 2.6 to daunomycin. 
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Figure 7. Glycosyl donor synthesis. 
 
Using cyclohexanol for a model system in place of expensive daunomycin, the 
glycosylation was performed using N-iodosuccinimide as the promoter affording a 
mixture of  alphaand beta isomers of the iodo-pyranose product which were separated by 
flash chromatography.
17
  Using triethylborane as the radical promoter in the presence of 
atmospheric oxygen and triphenyltinhydride, the iodo group was reduced to afford in 
good yield the 2-deoxy glycoside.
18
  We chose this method as typical reflux conditions 
(AIBN initiator) led to decomposition.  Removal of the acetate followed by oxidative 
cleavage of the diol using lead (IV) acetate produced the crude keto-aldehyde which was 
immediately subjected to NaBH4 reduction to furnish the acetal 2.10.
19
  as a 1:1 mixture 
isomers.  The mixture of  isomeric alcohols was treated with benzoic anhydride resulting 
in selective protection of the primary alcohol to afford 2.11.   
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Figure 8.  Cyclohexyl model system. 
 
Selective protection of the primary alcohol allowed for esterification of the 
remaining secondary alcohol using (S)-Mosher’s acid in an attempt to assign 
stereochemisty.  Comparing the chemical shifts of the diastereomers by 
1
H NMR, we 
assigned the relative stereochemistry at C3.  According to a paper by Riguera, the ap 
(antiperiplanar) conformer is the major contributor leading to an overall deshielding of 
the C3’ proton of one isomer relative the other, so we correlated the shifts expected of the 
corresponding Mosher esters to what we observed in our experimental evidence.
20
    This 
differs from the classical method Mosher analysis where both the (R)- and (S)- acids are 
used.  Traditionally it is the difference of the chemical shifts for substituents which 
indicates stereochemistry. 
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Figure 9. Mosher model comparison 
 
Table 1.  Chemical shifts of diastereomers 
Proton α-R α-S 
1 4.63 4.88 
3 5.27 5.35 
4 1.45 1.37 
5,5' 4.26 4.27,4.39 
6 4.01 4.1 
7 1.17 1.21 
1' 3.55 3.6 
 
 
 16 
 
Figure 10. Mosher’s Classical Model 
 
 Next we attempted to couple glycal 2.6 under identical conditions to N-acetyl 
daunomycin, unfortunately this reaction did not proceed. Apparently, the axial hydroxyl 
of the daunosamine sugar proves too unreactive towards NIS mediated glycosylation.  
Consulting work by Wang and co-workers we discovered that the identical daunomycin 
glycosyltion was reported using the a thioglycoside as the donor, the coupling was 
reportedly achieved using a silver salt as the promoter
21
.  Starting from rhamnal (2.1), we 
affected coupling with isopropyl alcohol in the anomeric position yielding a mixture of 
known monosaccharide after reduction.  Lewis acid catalyzed the exchange of the 
isopropyl acetal with thiophenol under the promotion of BF3·OEt2 furnished our desired 
thioglycoside donor. Starting from daunomycin hydrochloride salt, we were able to 
synthesize the trifluoroamide to provide glycosyl acceptor 2.14 in good yield.  
Unfortunately, all attempts to couple thioglycoside 2.17 with the N-trifluoroacetamide 
daunomycin failed to yield desired disaccharide leading instead to slow decomposition. 
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Figure 11.  Attempted coupling of DNR and glyosidic donor 
 
Conclusions 
 Future directions of this project would obviously entail formation of the 
disaccharide followed by the chemical transformation of the product to the requisite diol.  
It is hoped from that point we could derivatize the compound to form the Mosher ester to 
determine the stereochemistry about C3.  Once we know this, it is foreseeable that 
derivatization of the natural product in the same manor would tell us if the compound 
were a mixture of R and S isomers about C3 and determine which configuration we have.  
However, if the spectra of the synthetic product and the natural do not match, our 
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assumption of C3 being the source of the diastereomers is incorrect and either it is a 
mixture of anomeric products or D and L sugars.  To determine this, it would be possible 
to start from the D-rhamnose substrate and compare the isomeric series.  Despite the 
prevalence of baumycin, it is surprising that the stereochemistry still remains unknown.  
Given the fragile nature of the acetal, this natural product is extremely difficult to work 
with. 
As an interesting side project Brian Bachmann’s lab, which isolated the product in 
question, has discovered an interesting oxidative enzyme.  It is proposed that this enzyme 
may be responsible for oxidizing the disaccharide to effect a Criegee type fragmentation 
to the keto-aldehyde.  With the disaccharide in hand, it would be interesting to see if this 
enzyme could in fact produce the product of the oxidative cleavage.  With some positive 
results, potential justification for exploring more isolated cave ecosystems in attempt to 
discover more novel natural products could be found.  The discovery of this new enzyme 
could also be a significant find. 
 19 
 
Figure 12. Criegee Rearrangement 
 20 
Experimental 
 
To D-galactal (3.125 g, 21.4 mmol) in DMF (8.5 mL) was added Et3N (8.9 mL) with 
stirring at room temperature.  After 30 min, TIPSCl (5.15 mL, 23.5 mmol) was added and 
the reaction was stirred for 24 hours.  The reaction was washed with 50mL of H2O and 
extracted 3x30mL with EtOAc, dried (MgSO4), concentrated and purified by silica gel 
chromatography with Hexane/EtOAc (3:1).   Product was obtained as a pale, yellow oil 
(5.048g, 78%) . The 1H NMR was identical to published data.
 8
 
 
To 6-O-TIPS-d-galactal (5.048g,16.7mmol) in dichloromethane (104mL) at room 
temperature was added 2,2-dimethoxypropane (6.14Ml, 50.1mmol) followed by a 
catalytic amount of DDQ (379mg, 1.67mmol).  The reaction was allowed to stir at room 
temperature for 3 days at which time the solvent was evaporated and the residue was 
purified by flash chromatography with Hexane/EtOAc (30:1) to give 2.877g (50%) of 
viscous oil.  The 1H NMR was identical to published data.
 8
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To the acetonide (698.7mg, 2.09mmol) in CH3CN was added CAN (3.355g, 6.12mmol) 
followed by NaN3 (265mg, 4.08mmol) at -20˚C with vigorous stirring.  After 20 hours 
the reaction appears to be complete.  It was diluted with EtOAc , washed with cold H2O 
and saturated brine solution, then dried (MgSO4), concentrated  and the residue was 
purified by flash chromatography Hexane/EtOAc (40:1) to give 298mg (32%) of a clear 
oil. The 1H NMR was identical to published data.
 8
 
 
To the azido-nitrate (289mg, .648mmol) in acetonitrile (2.2mL) at 0˚C was added 
Hunig’s base (113uL, .648mmol) followed by PhSH (197uL, 1.944mmol) slowly 
dropwise.  The reaction was allowed to stir for 2 hours and the solvent was evaporated.  
The product was purified by flash chromatography Hexane/EtOAc (25:1) to give 160mg 
(61%) of a clear oil.  The 1H NMR was identical to published data.
8
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To the azido sugar (100mg, .249mmol) in dichloromethane (2.5mL) was added K2CO3 at 
0˚C followed by trichloroacetonitrile (250uL, 2.49 mmol) with stirring.  After five hours, 
the reaction was filtered through Celite and concentrated.  The residue was purified by 
flash chromatograpy Hexane/EtOAc (25:1) to give 92.4mg (70%) of a white solid and 
21.4mg of starting material.  The 1H NMR was identical to published data.
 8
 
 
To a mixture of peptide(230mg,.54mmol) and trichloroacetimidate (200mg, ) in THF 
(3.6mL) was added freshly activated, powdered 4A molecular sieves (800mg).  After 30 
minutes of stirring, the reaction was cooled to -78˚C and TMSOTf (33uL in .76mL of 
THF) was added dropwise.  After stirring for two hours, the reaction was quenched with 
Et3N and filtered through Celite with EtOAc.  The reaction was washed with H20 and 
saturated brine, dried (MgSO4), concentrated and purified by flash chromatography 
Hexane/EtOAc (10:1) with 2% Et3N.  Product was obtained as a clear oil (161mg, 56%) 
 
 
To the glycopeptide (400.4mg, .50mmol) in MeOH (8.3mL) was added I2 (381mg, 
1.50mmol) with stirring at room temperature.  The reaction was allowed to stir overnight 
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(16hours) and was diluted with EtOAc. It was quenched by washing with saturated Na2-
S2O3 then washed with brine and dried (MgSO4 ) and concentrated.  Purification via 
column with 1:1 Hex:EtOAc gave 208mg of white foam (69%).  The 1H NMR was 
identical to published data.
12
 
 
To the triol (66mg, .11mmol) in DMF (.55mL) was added imidazole (30mg, .44mmol) 
with stirring.  The reaction was cooled to 0˚C and TBSCl (33mg, .22mmol) was added.  
The reaction was allowed to slowly warm to rt and was stirred overnight (16hrs) then 
diluted with EtOAc and washed with H2O then brine solution.  The organics were dried 
(MgSO4), concentrated, and purified by flash chromatography with 2:1 Hex:EtOAc to 
give a white foam (55mg, 70%), 
 
To a solution of Ac2O(30.6mL, .324mol) was added l-rhamnose monohydrate (10g, 
.055mol) slowly.  A water bath was used to maintain the reaction at room temperature.  
After stirring for 5hr, 33%HBr in AcOH (18.8mL, .104mol) was added dropwise and the 
reaction was stirred overnight (17hr).  A buffered solution was prepared by mixing 
NaOAc·3H2O (7.076g, 52mmol) in water (60mL) with AcOH (61mL) at 0
o
C with 
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mechanical stirring.  The crude bromide was added slowly, dropwise at 0
o
C.  The 
reaction was stirred 4hr at room temperature then filtered through celite and extracted 
4x100mL of EtOAc.  The organics were washed with cold water cold saturated sodium 
bicarbonate, saturated brine and water .  The organics were dried (MgSO4) and 
concentrated.  The residue was purified by gradient elution of 6:1 Hex:EtOAc to 4:1 
Hex:EtOAc until elution.  A white crystalline solid (6.99g, 60%) was obtained.  The 1H 
NMR was identical to published data.
3
 
 
To MeOH(120mL) was added l-rhamnal (2.52g, 11.8mmol) with stirring followed by 
K2CO3 (4.88g, 35.34mmol) at ambient temperature.  After 24hr the solvent was 
evaporated and the product was dissolved in Et2O/EtOAc and washed with water to 
remove residual salt.  The product was dried (MgSO4) and concentrated to yield l-
rhamnal (1.33g, 87%). The 1H NMR was identical to published data.
16
 
 
To a solution of EtOAc (220mL) and AcOH (4.8mL) was added l-rhamnal (2.871g, 
22.1mmol) with stirring at ambient temperature.  After 17hr the reaction was filtered 
through a mixture of celite/silica gel to remove Cr.  The organics were washed with 
saturated NaHCO3 and dried (MgSO4).  Evaporation of the solvents yields white crystals 
 25 
(1.86g, 65%). 
1
H NMR (CDCl3, 300MHz) 7.38 (d, J = 5.7Hz, 1H), 5.45 (d J = 5.8Hz, 
1H), 4.19 (dq, 1H), 3.97 (d, J = 13Hz, 1H), 1.56 (d, J = 6.2Hz, 3H). The 1H NMR was 
identical to published data.
16
 
 
 
To THF (72mL) at-78
 o
C was added the glycal (1.86g,14.4mmol) with stirring.  To this 
was added MeLi (18mL, 1.6M in Hexanes).  After 30 min an additional aliquot of MeLi 
was added to push the reaction to completion.  The reaction was poured onto ice and 
extracted with EtOAc.  The organics were dried (MgSO4) and then concentrated.  Flash 
chromatography (3:1 Hex:EtOAc) gave 943mg (46%) of product (1:4). 
1
H NMR 
(CDCl3,300MHz) 4b: 6.18 (d J = 6Hz, 1H), 4.69 (d, J = 6Hz, 1H), 3.86 (m, 1H) 3.62 (d, J 
= 9.9Hz, 1H) 3.02 (bs 1H), 2.32(bs, 1H) 1.37 (d, J = 6.2Hz, 3H), 1.32 (s, 3H) 
4a: 6.34(d, J = 5.9Hz, 1H), 4.81 (d, J = 5.9Hz, 1H), 3.71 (m, 1H), 3.23 (t, J = 10.1Hz, 
1H), 2.49 (d, J = 9.9Hz, 1H), 1.80 (s, 1H), 1.40 (d, J = 6.2Hz, 3H), 1.34 (s, 3H). 
 
To the glycal (100mg, .694mmol) in pyridine (6mL) was added Ac2O (131µL, 
1.39mmol) and a catalytic amount of DMAP.  The reaction was stirred for 24hr then 
 26 
azeotroped with toluene.  Flash chromatography with 2:1 Hex:EtOAc yield product as a 
clear oil (115mg, 89%): [α]20D = -92.29° (c. 0.0858, CHCl3) 
1
H NMR (CDCl3, 400MHz) 
6.19 (d, J = 6Hz, 1H), 4.90 (d, J = 10Hz, 1H), 4.73 (d, J = 6Hz, 1H), 3.93 (dq, J = 10Hz, J 
= 6Hz, 1H), 2.11(s, 3H), 1.26 (s, 3H), 1.24 (d, J = 6Hz, 3H) 
13
C: 171.2, 142.3, 108.0, 
78.8, 71.9, 69.6, 24.6, 20.8, 17.3. IR: 3449, 2984, 1735, 1649, 1453, 1376, 1237, 1078, 
1055. 
 
To the glycal (100mg, 0.694mmol) in pyridine (6mL) was added Ac2O (131µL, 
1.39mmol) and a catalytic amount of DMAP.  The reaction was stirred for 24hr at which 
time an additional aliquot of Ac2O was added.  The reaction was stirred another 24hr then 
azeotroped with toluene.  Flash chromatography with 2:1 Hex:EtOAc yield the product as 
a clear oil (96mg, 74%): [α]20D = -134.49° (c. 0.024, CHCl3.) 
1
H NMR (CDCl3, 400MHz) 
6.30 (d, J = 6Hz, 1H), 4.79 (d, J = 10.4Hz, 1H) 4.74 (d, J = 6Hz, 1H) 4.12 (dq, J = 6.4Hz, 
J = 12.8Hz) 2.13 (s, 3H), 1.20 (d, J = 6.4 Hz) 1.19 (s, 3H).  
13
C: 170.2, 145.1, 105.6, 76.6, 
69.3, 66.5, 26.1, 20.7, 16.8. IR: 3457, 2980, 2937, 1739, 1644, 1375, 1244, 1137, 1053. 
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To a solution of acetylated glycal (115mg, .617mmol) in dry CH3CN was added 
cyclohexanol (77µL,.741mmol) followed by NIS (208mg,.926mmol).  The reaction was 
stirred for 3 days.  The reaction was washed with saturated sodium thiosulfate and 
saturated sodium bicarbonate.  The aqueous layer was extracted with EtOAc (2x10mL) 
and dried (MgSO4).  The organics were concentrated and the residue was purified to 
provide by flash chromatography alpha and beta  glycosides (2:1 alpha: beta, 
105mg,41%) where some residual cyclohexanol remained in the fraction with the beta 
product. Alpha: [α]20D = -34.04° (c. 0.0228, CHCl3)
 1
H NMR (CDCl3, 400MHz)  5.35 (d, 
J = 2.8Hz, 1H), 4.94 (d, J = 8.4Hz, 1H), 4.33 (d, J = 2.8Hz, 1H), 3.94 (m, 1H), 3.59 (m, 
1H), 2.32 (s, 1H), 2.12 (s, 3H), 1.80 (m, 2H), 1.70 (m, 2H), 1.50 (s, 3H), 1.22 (d, J = 
9.2Hz, 3H)  
13
C: 170.8, 99.8, 76.8, 76.3, 71.7, 67.6, 47.1, 33.2, 31.5, 25.6, 23.9, 23.6, 
22.3, 20.9, 17.7  IR: 3482, 2932, 2857, 1745, 1451, 1376, 1233, 1036.  LCMS (M+H
+
) = 
412.26, found (M+Na
+
) = 435.1 
Beta: [α]20D = -42.93° (c. 0.027, CHCl3) 
1
H NMR (CDCl3, 400MHz) 4.76 (d, J = 9.6Hz, 
1H), 4.57 (d, J = 9.2Hz, 1H), 4.08 (d, J = 8.8Hz, 1H), 3.52-3.63 (m, 2H), 2.45 (s, 1H), 
2.12 (s, 3H), 1.36 (s, 3H), 1.20 (d, J = 6Hz, 3H).  
13
C:  170.7, 99.5, 78.0, 76.9, 73.53, 
69.0, 46.5, 33.2, 31.4, 25.5, 23.9, 23.8, 21.6, 20.9, 17.7.  IR: 3435, 2934, 1732, 1644, 
1231, 1016.  LCMS (M+H
+
) = 412.26, found (2M+ Na
+
) = 847.1. 
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To the iodopyranoside (72mg, .175mmol) in PhMe (1.8mL) at 0
o
C was added Ph3SnH 
(74mg, .210mmol) and BEt3(1.0M in Hexanes, 52µL, .052mmol) with stirring.  The 
reaction was allowed to come to room temperature and stirred for 3hr open to 
atmosphere.  The solution was washed with saturated potassium fluoride for 1hr and 
filtered through celite.  The organic phase was dried (MgSO4) and concentrated.  The 
residue was chromatographed 5:1 Hex:EtOAc to give 42mg (84%) of white solid.  [α]20D 
= -132.81° (c. 0.0205, CHCl3)  
1
H NMR (CDCl3, 400MHz) 4.98 (d, J = 3.2Hz, 1H) 4.58 
(d, J = 9.6Hz, 1H), 3.82 (dq, J = 6Hz, J = 3.6Hz), 3.52 (m, 1H), 2.40 (s, 1H), 2.12 (s, 3H), 
1.88-2.00 (m, 2H), 1.69-1.78 (m, 4H), 1.59 (s, 3H), 1.49 (m, 1H), 1.24-1.35 (m, 5H), 1.14 
(d, J = 6.4Hz, 3H). 
13
C: 171.6, 94.8, 80.8, 74.5, 70.9, 64.9, 44.3, 33.3, 31.4, 25.7, 24.0, 
23.6, 22.7, 21.0, 17.8.  IR: 3472, 2933, 2857, 1742, 1727, 1452, 1374, 1237, 1126, 1048, 
1014.  LCMS (M+H
+
) = 286.2, found (M+ Na
+
) 309.2. 
 
To the glycoside (54mg, .131mmol) in PhMe (1.3mL) at 0
o
C was added Ph3SnH (55mg, 
.157mmol) and BEt3 (1.0M in Hexanes, 39µL, .039mmol) with stirring.  The reaction was 
allowed to come to room temperature and stirred for 3hr open to atmosphere.  The 
solution was washed with saturated potassium fluoride for 1hr and filtered through celite.  
The organic phase was dried (MgSO4) and concentrated.  The residue was 
chromatographed 5:1 Hex:EtOAc to give 29mg (77%) of white solid.  [α]20D = 12.65° (c. 
0.0109, CHCl3).  
1
H NMR (CDCl3, 400MHz) 4.65 (dd, J = 9.2Hz, J = 2Hz, 1H) 4.56 (d, J 
= 7.6Hz, 1H) 3.62 (m, 1H), 3.48 ( dq, J = 8.8Hz, J = 6Hz, 1H), 2.67 (s, 1H), 2.11 (s, 3H) 
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1.7-2.0 (m, 7H), 1.20-1.53 (m, 6H) 1.24 (s, 3H), 1.21 (d, J = 6Hz, 3H).  
13
C: 171.5, 97.0, 
80.2, 76.5, 71.2, 69.5, 45.9, 33.6, 31.9, 25.6, 24.2, 24.1, 21.4, 21.0, 18.4.  IR: 3436, 2982, 
2932, 2856, 1733, 1370, 1229, 1099, 1059, 1050. LCMS (M+H
+
) = 286.2, found (M+ 
Na
+
) 309.2. 
 
To MeOH (1.5mL) was added the protected glycoside (42mg, .147mmol) with stirring 
followed by K2CO3 (2mg, .015mmol) at ambient temperature.  After 24hr the solvent was 
evaporated and the product dissolved in EtOAc then filtered through celite to give the 
deacetylated product (35mg, 97%).  [α]20D = -88.57° (c. 0.0205, CHCl3).   
1
H NMR 
(CDCl3, 400MHz) 4.97 (d, J = 4Hz, 1H) 3.70 (dq, J = 6.4Hz, J = 9.6Hz, 1H), 3.54 (m, 
1H), 3.25 (d, J = 9.6Hz, 1H), 2.29 (bs, 1H) 1.83-1.95 (m, 3H), 1.77 (m, 2H), 1.70 (m, 2H) 
1.50 (m, 1H), 1.43 (s, 3H), 1.27 (d, J = 6.4Hz, 3H), 1.25(m, 3H). 
13
C: 94.9, 79.9, 74.2, 
71.7, 66.6, 43.7, 33.4, 31.4, 25.8, 24.0, 23.7, 22.1, 18.0.  IR: 3400, 2931, 2856, 1451, 
1327, 1125, 1054, 1011.  LCMS (M+H
+
) = 244.2, found (M+ Na
+
) 267.2. 
 
To the protected glycoside (22mg, .077mmol) in MeOH (1mL) with stirring was added 
K2CO3 (ca 1mg,) at ambient temperature.  After 24hr the solvent was evaporated and the 
product dissolved in EtOAc then filtered through Celite to give the deacetylated product 
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(16mg, 85%).  [α]20D = 19.39° (c. 0.0109, CHCl3).   
1
H NMR (CDCl3, 400MHz) 4.63 (dd, 
J = 9.6Hz, J = 2 Hz, 1H), 3.60 (m, 1H), 3.34 (dq, J = 9.6Hz, J = 6Hz, 1H) 3.23 (d, 9.2Hz, 
1H), 2.71 (s, 1H), 2.41 (s, 1H), 1.30 (d, J = 6Hz, 3H), 1.25 (s, 3H), 1.2-1.4 (m, 6H).  
13
C: 
97.0, 79.5, 72.0, 70.7, 45.7, 33.6, 31.9, 25.5, 24.2, 24.1, 20.4, 18.3.  IR: 3400, 2931, 
2856, 1450, 1363, 1073, 1050, 1023.  LCMS (M+H
+
) = 244.2, found (M+ Na
+
) 267.2. 
 
To the free diol (29mg, .120mmol) in PhMe  (1.2mL) was added lead (IV) acetate (57mg, 
.132mmol) with stirring at rt.  After two hours, the reaction was filtered through a short 
silica plug.  The crude keto-aldehyde was immediately concentrated to give a crude, 
yellow oil (29.0 mg, 99%) and redissolved in MeOH (1.2mL) at 0˚C and NaBH4 
(.479mmol) was added with stirring.  After 1.5hr, the reaction was evaporated, dissolved 
in ether, and filtered through a short silica plug to give 22.8mg (77%) of product.  The 
diol proved unstable and necessitated use immediately. Crude Aldehyde: 
1
H NMR 
(CDCl3, 400MHz) 9.58 (d, 2.4Hz, 1H), 5.03 (dd, 4.4Hz, 6.4Hz, 1H), 3.95 (m, 1H), 3.42 
(m, 1H), 2.82 (dd, 6.4Hz, 15.2Hz, 1H), 2.67 (dd, 4.4Hz, 7.2Hz, 1H), 2.18 (s, 3H), 1.6-1.9 
(m, 5H) 1.5 (m, 1H), 1.18-1.28 (m, 7H) Crude diol mixture 0.9:1.0 : 4.84(t, 4.8Hz, 1H) 
4.78( t, 5.6Hz, .9H), 4.03 (m, 1.9H), 3.82 (m, 1.9H), 3.48 (m, 5.7H), 1.9 (m, 4.2H), 1.76 
(m, 7.4H), 1.53 (m, 1.9H) 1.21-1.41 (m, 10H), 1.18 (m, 6H), 1.14 (m, 5.9H) 
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To the free diol (37mg, .12051mmol) in PhMe  (1.5mL) was added lead (IV) acetate 
(74mg, .167mmol) with stirring at rt.  After one hour, the reaction was filtered through a 
short silica plug.  The crude keto-aldehyde was immediately concentrated to give a crude, 
yellow oil (35.8 mg, 98%) and redissolved in MeOH (1.5mL) at 0˚C and NaBH4(22mg, 
.591mmol) was added with stirring.  After 1.5hr, the reaction was evaporated, dissolved 
in ether, and filtered through a short silica plug to give 21.5mg (59%) of product.  The 
diol proved unstable and necessitated use immediately. Crude Aldehyde: 
1
H NMR 
(CDCl3, 400MHz) 9.59 (d, 1.6Hz, 1H), 5.12 (t, 5.2Hz, 1H), 4.11 (m, 1H), 3.50 (m, 1H), 
2.79 (dd, 5.6Hz, 3.2Hz, 2H), 2.19 (s, 3H) 1.8 (m, 3H), 1.7 (m, 3H), 1.5 (m, 1H), 1.2 (m, 
5H).  Diol mixture 1:1.2 diastereomers: 5.02 (t, 4.8Hz, 1H), 4.88 (t, 4.4Hz, 1.6H), 4.17 
(m, 1H), 4.0 (m, 2.4H), 3.72 (m, 3.3H), 3.44(m, 9.9H) 1.6-1.8 (m, 18H), 1.04-1.20 
(m,11H) 
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To the reduced diol (22.8mg, .093mmol) in pyridine (1mL) was added benzoic anhydride 
(26mg, .102mmol) at room temperature with stirring.  A catalytic amount of DMAP was 
added to the reaction and stirred for three hours.  The reaction was diluted with ethyl 
acetate and washed with saturated sodium bicarbonate solution, dried (MgSO4) and 
concentrated.  The product was purified by flash chromatography with Hexanes:EtOAc 
(3:1) to give 9.9mg of product (30%).
1
H NMR (CDCl3, 400MHz) 8.08 (d, 8.8Hz, 2H), 
7.65 (m, 1H), 7.54 (t, 5.6Hz, 2H), 5.00 (m, 1H), 4.35 (m, 1H), 4.27 (m, 1H), 4.17 (m, 
1H), 3.95 (m, 1H), 3.64 (m, 1H), 1.86 (m, 2H), 1.73 (m, 2H), 1.67(m, 2H), 1.49 (m, 1H), 
1.2-1.30 (10H) 1.15 (m, 3H) 
 
To the reduced diol (21.5mg, .087mmol) in pyridine (.9mL) was added benzoic 
anhydride (24mg, .096mmol) at room temperature with stirring.  A catalytic amount of 
DMAP was added to the reaction and stirred for three hours.  The reaction was diluted 
with ethyl acetate and washed with saturated sodium bicarbonate solution, dried (MgSO4) 
and concentrated.  The product was purified by flash chromatography with 
Hexanes:EtOAc (3:1) to give 14mg of product (46%).
1
H NMR (CDCl3, 400MHz) 8.1 (m, 
2H), 7.69 (m, 1H), 7.56 (t, 8Hz, 2H), 5.06 (t, 1H), 4.3 (m, 1H), 4.16 (m, 1H), 3.80 (m, 
1H), 3.66 (m, 1H), 1.93 (m, 2H), 1.70 (m, 4H), 1.53(m, 1H), 1.33 (d, 6Hz, 1H), 1.2-1.40 
(6H) 1.15 (d, 6Hz, 3H) 
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To 9.9mg of the benzoate (.028mmol) in DCM (.3mL) was added S-Mosher acid (8.0mg, 
.034mmol), DCC (8.0mg, .037mmol) and a small crystal of DMAP to catalyze the 
reaction.  The reaction was stirred for 24 hours at room temperature at which time an 
additional equivalent of Mosher acid and DCC were added to drive the reaction to 
completion.  After another 24 hours, the solvent was evaporated and the product purified 
by flash chromatography Hexanes:EtOAc to give a mixture of diastereomers (7.8mg, 
49%).  These were separable on a silica column by HPLC using Hexane:EtOAc (5:1) to 
give the R- and S- esters. 
1
H NMR (CDCl3, 400MHz) R-Ester: 8.08 (m, 2H), 7.7 (m, 1H), 
7.67 (m¸ 2H), 7.5-7.63 (m, 4H), 5.27 (m, 1H), 4.62 (dd, 3.6Hz, 7.6Hz, 1H), 4.25 (m, 2H), 
4.0 (m, 1H), 3.62 (d, 1.2Hz, 3H), 3.54 (m, 1H), 1.75-2.00 (m, 6H), 1.67 (m, 2H), 1.47 (m, 
1H), 1.44 (d, 5.6Hz, 3H). 
13
C 166.5, 166.2, 133.8, 133.3, 131.0, 130.5, 129.4, 129.3, 
129.3, 129.1, 128.0, 127.9, 125.4, 98.2, 74.7, 72.2, 70.7, 68.6, 55.7, 42.7, 34.1, 32.7, 26.2, 
24.5, 24.4, 20.3, 17.8.  S-Ester: 8.08 (m, 2H), 7.5-7.7 (m, 9H), 5.35 (m, 1H), 4.80 (dd, 
4.4Hz, 5.6Hz, 1H), 4.38 (dd, 5.6Hz, 11.6Hz, 1H), 4.27 (dd, 4.4Hz, 11.2Hz, 1H), 4.17 (m, 
1H), 3.60 (d, 0.8Hz, 3H), 1.84-1.98 (m, 5H), 1.68 (m, 3H), 1.2-1.4 (m, 7H), 1.33 (d, 
5.6Hz, 3H), 1.28 (d, 5.6Hz, 3H) 
 13
C: 166.5, 166.2, 133.8, 133.6, 133.0, 131.1, 130.4, 
130.1, 130.0, 129.3, 129.23, 129.18, 129.1, 128.4, 128.2, 98.2, 75.0, 72.0, 70.5, 68.7, 
55.7, 42.4, 33.8, 33.2, 26.2, 24.5, 24.4, 20, 17.6. 
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To 14mg of the benzoate (.040mmol) in DCM (.4mL) was added S-Mosher acid 
(11.2mg, .048mmol), DCC (11.0mg, .052mmol) and a small crystal of DMAP to catalyze 
the reaction.  The reaction was stirred for 24 hours at room temperature at which time an 
additional equivalent of Mosher acid and DCC were added to drive the reaction to 
completion.  After another 24 hours, the solvent was evaporated and the product purified 
by flash chromatography Hexanes:EtOAc (5:1) to give a mixture of diastereomers (12mg, 
53%).  These diastereomers proved inseparable thus far by HPLC.
 1
H NMR (CDCl3, 
400MHz) 8.08 (m, 2H), 7.67 (m, 1H), 7.53 (m, 6H), 5.32 (m, 1H), 4.92 (dd, 4.8Hz, 
6.8Hz, .6H), 4.65 (dd, 4.4Hz, 6.8Hz, .4H), 4.32 (m, 2H), 4.05-4.18 (m, 1H), 3.70 (m, 
.6H), 3.66 (s, 1.2H), 3.58 (s, 1.65H), 3.48 (m, .4H), 2.84( bs, 3.59H), 1.92 (m, 3H), 1.7 
(m, 2.4H), 1.53 (m, 1H), 1.40 (d, 6Hz, 1.6H), 1.28-1.34 (m, 7H). 
 
To the acetonide (1.5345g, 8.24mmol) in acetonitrile (82mL) was added NIS (2.781g, 
12.36mmol) and IPA (756μL, 9.89mmol) at ambient temperature with stirring.  After 3 
days, the reaction was washed with Na2S2O3 solution and saturated NaHCO3.  The 
aqueous layer was extracted with EtOAc and the organics were dried (MgSO4) and 
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concentrated.  Flash chromatography provided a clear oil mixture of the alpha and beta 
anomers. 
 
To the isopropyl iodo-glycoside (816mg, 2.19mmol) in toluene (22mL) at 0˚C was added 
Ph3SnH (924mg, 2.64mmol) and 1.0M BEt3 in hexanes (.66mL, .66mmol) open to 
atmosphere and allowed to warm to room temperature for 3 hours.  The solvent was 
evaporated and the residue was purified by flash chromatography to give 543g (100%) of 
white solid.  The 1H NMR was identical to published data.
 21
.
 
 
To the isopropyl glycoside (359mg, 1.46mmol) and PhSH (149μL,1.46mmol) in toluene 
(14.6mL) at 0˚C was added BF3·EtO2 (166µL, 1.31mmol) and the reaction was allowed 
to slowly come to room temperature and stirred for 3 hours.  The starting material was 
replaced by a UV active spot and the reaction was washed with 5% NaOH and separated.  
The organics were dried (MgSO4), concentrated, and purified by 10:1 Hex:EtOAc to give 
378mg of compound (87%).  The 1H NMR was identical to published data.
21
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APPENDIX A: SPECTRA 
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Figure A1 The 400MHz 
1
H NMR of 1.3 in CDCl3 
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Figure A2 The 400MHz 
1
H NMR of 1.4 in CDCl3 
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Figure A3 The 400MHz 
1
H NMR of 1.5 in CDCl3 
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Figure A4 The 400MHz 
1
H NMR of 1.6.1 in CDCl3 
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Figure A5 The 500MHz 
1
H NMR of 1.6.2 in CDCl3 
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Figure A6 The 400MHz 
1
H NMR of A in CDCl3 
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Figure A7 The 300MHz 
1
H NMR of 2.2 in CDCl3 
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Figure A8 The 300MHz 
1
H NMR of 2.3 in CDCl3 
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Figure A9 The 400MHz 
1
H NMR of 2.4 in CDCl3 
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Figure A10 The 400MHz 
1
H NMR of 2.5a in CDCl3 
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Figure A11 The 400MHz 
1
H NMR of 2.5b in CDCl3 
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Figure A12 The 400MHz 
1
H NMR of 2.6a in CDCl3 
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Figure A13 The 125MHz 
13
C NMR of 2.6a in CDCl3 
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Figure A14 The 400MHz 
1
H NMR of 2.6b in CDCl3 
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Figure A15 The 125MHz 
13
C NMR of 2.6b in CDCl3 
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Figure A16 The 400MHz 
1
H NMR of 2.7a in CDCl3 
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Figure A17 The 125MHz 
13
C NMR of 2.7a in CDCl3 
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Figure A18 The 400MHz 
1
H NMR of 2.7b in CDCl3 
 55 
 
 
Figure A19 The 125MHz 
13
C NMR of 2.7b in CDCl3 
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Figure A20 The 400MHz 
1
H NMR of 2.8a in CDCl3 
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Figure A21 The 125MHz 
13
C NMR of 2.8a in CDCl3 
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Figure A22 The 400MHz 
1
H NMR of 2.8b in CDCl3 
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Figure A23 The 125MHz 
13
C NMR of 2.8b in CDCl3 
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Figure A24 The 400MHz 
1
H NMR of 2.9a in CDCl3 
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Figure A25 The 125MHz 
13
C NMR of 2.9a in CDCl3 
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Figure A26 The 400MHz 
1
H NMR of 2.9b in CDCl3 
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Figure A27 The 125MHz 
13
C NMR of 2.9b in CDCl3 
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Figure A28 The 400MHz 
1
H NMR of 2.10.1b in CDCl3 
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Figure A29 The 400MHz 
1
H NMR of 2.10.1a in CDCl3 
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Figure A30 The 400MHz 
1
H NMR of 2.10.2a in CDCl3 
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Figure A31 The 400MHz 
1
H NMR of 2.10.2b in CDCl3 
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Figure A32 The 400MHz 
1
H NMR of 2.11a in CDCl3 
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Figure A33 The 400MHz 
1
H NMR of 2.11b in CDCl3 
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Figure A34 The 600MHz 
1
H NMR of 2.12c-d in CDCl3 
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Figure A35 The 150MHz 
13
C NMR of 2.12c-d in CDCl3 
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Figure A36 The 600MHz 
1
H NMR of 2.12b in CDCl3 
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Figure A37 The 150MHz 
13
C NMR of 2.12b in CDCl3 
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Figure A38 The 600MHz 
1
H NMR of 2.12a in CDCl3 
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Figure A39 The 150MHz 
13
C NMR of 2.12a in CDCl3 
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Figure A40 The 400MHz 
1
H NMR of 2.15 in CDCl3 
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Figure A41 The 125MHz 
13
C NMR of 2.15 in CDCl3 
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Figure A42 The 400MHz 
1
H NMR of 2.16 in CDCl3 
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Figure A43 The 400MHz 
1
H NMR of 2.17 in CDCl3 
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